- Home
- USAU vs OTLK Comparison
USAU vs OTLK Comparison
Compare USAU & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | OTLK |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 249.6M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | USAU | OTLK |
|---|---|---|
| Price | $13.92 | $0.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $26.50 | $5.03 |
| AVG Volume (30 Days) | 132.1K | ★ 3.4M |
| Earning Date | 09-11-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.11 | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,402,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.23 | $0.16 |
| 52 Week High | $23.72 | $2.54 |
Technical Indicators
Market Signals| Indicator | USAU | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 33.52 |
| Support Level | $13.53 | $0.50 |
| Resistance Level | $16.23 | $0.70 |
| Average True Range (ATR) | 0.48 | 0.04 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 9.14 | 21.23 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.